Top Markets
#1 PulseChain PulseChain +45.01%
#2 RedStone RedStone +18.29%
#3 Glidr Glidr +11.78%
#4 SkyAI SkyAI +10.14%
#5 Bitway Bitway +9.91%
#6 OPENLOOT OPENLOOT +8.85%
#7 Pump.fun Pump.fun +7.99%
#8 Unit Pump Unit Pump +7.99%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.84%
#10 Monad Monad +6.79%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rank in Stocks #28046
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Share Price
$0.55
Last synced: 2025-02-11
Market Cap
$28.90M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Marinus Pharmaceuticals, Inc. (MRNS)

Category

Healthcare
P/E ratio for Marinus Pharmaceuticals, Inc. (MRNS)
P/E ratio as of August 2026 TTM: -0.21
According to Marinus Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.21. At the end of 2022 the company had a P/E ratio of -1.96.
P/E ratio history for Marinus Pharmaceuticals, Inc. from 2012 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.21 -79.70%
2023 -1.03 -47.31%
2022 -1.96 83.00%
2021 -1.07 -14.10%
2020 -1.25 127.96%
2019 -0.55 -31.48%
2018 -0.80 -68.56%
2017 -2.54 1,378.30%
2016 -0.17 -85.01%
2015 -1.15 -23.59%
2014 -1.50 -50.96%
2013 -3.06 -73.27%
2012 -11.45 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -14,064.75%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 3,694.74%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -14,743.33%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -15,624.10%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.